Načítá se...
Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study
SETTING: Phase II trials for bedaquiline (BDQ) and delamanid (DLM) were completed by 2011 and the drugs were approved by stringent regulatory authorities for the treatment of multidrug-resistant tuberculosis (MDR-TB) between 2012 and 2014. Manufacturers established ‘early access’ mechanisms to provi...
Uloženo v:
| Vydáno v: | Public Health Action |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
International Union Against Tuberculosis and Lung Disease
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436488/ https://ncbi.nlm.nih.gov/pubmed/30963040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/pha.18.0078 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|